Recce Enters into USA Department of Defense R&D Agreement

Recce Pharmaceuticals has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), supported by the Defense Threat Reduction Agency. This agreement will involve testing RECCE® 327 (R327) against biodefense pathogens in high biocontainment conditions. Additionally, the company has been awarded a US$2 million grant for a burn wound program by the U.S. Department of Defense. The testing at USAMRIID complements Recce's existing partnerships and initiatives in the U.S. Government's defense sector. RECCE® 327 is a synthetic anti-infective with broad-spectrum effectiveness against bacterial superbugs. It has shown promising results in human clinical trials and pre-clinical studies. The partnership with USAMRIID aligns with the global effort to combat antibiotic resistance and develop new therapeutic compounds. Investors are invited to inquire further about the implications of this partnership and the potential impact on Recce Pharmaceuticals' development pipeline. For more information, visit the company's website and stay updated on our progress in addressing critical global health challenges.